FIELD: medicine. SUBSTANCE: method involves carrying out clinical and electroencephalographic examination, determining risk factors and calculating coefficients F1 and F2 from formulas. F1=-1.81+ 1.55 a1 + 1.02 a2 +2.14 a3 - 0.04 a4 + 0.58 a5 + 1.82 a6 + 1.21 a7 - 0.08 a8 +1.6 a9 - 0.83 a10 + 1.26 a11 - 0.84 a12 + 1.40 a13; F2=-6.79+ 1.39 a1 + 0.75 a2 +4.21 a3 - 0.35 a4 + 1.78 a5 + 3.68 a6 + 2.05 a7 - 0.81 a8 +2.48 a9 - 2.03 a10 + 4.05 a11 - 0.27 a12 + 4.15 a13; where digital members are the constants of discriminant equation and discrimination coefficients, a1-13 are the gradations and numeric values of risk factors (a1 - age, a2 - body mass excess, a3 - smoking, a4 - arterial hypertension, a5 - psychoemotional stress, a6 - hypokinesia, a7 - significant craniocerebral trauma in anamnesis, a8 - heredity aggravated with cardiovascular diseases, a9 - bronchial asthma duration, a10 - asthmatic statuses availability in anamnesis, a11 - bronchial asthma severity degree, a12 - paroxysmal activity available on electroencephalogram, a13 - pathological electroencephalographic response to functional tests with hyperventilation and photostimulation. F2≥F1 being the case, diencephalic encephalopathy development is to be predicted in bronchial asthma patient showing no manifestations of cerebrovascular pathology. EFFECT: enhanced accuracy of prognosis. 1 tbl
